





MEDICAL DEVICES CHANGE OF LEGISLATION What you need to know!



STEP	INTENTION / ACTION
1 Pre-assessment	Brief management to ensure a clear understanding of the importance and business implications of the MDR
	Consider organisational challenges: management awareness, staffing capability and availability, budget implications
2 Gap analysis and actions resulting from this	Assess impact on products, internal resources, organisation and budget
	Check new classification rules (MDR Classes I, IIa, IIb and III) and confirm conformity assessment routes for existing and future products
	Check the new definition of MD, particularly with respect to its expanded scope. This also applies to products covered in Annex XVI
	Review the changes needed to existing technical documentation (Technical Files)
	Review and upgrade quality management system (QMS) (point 3 below)
	Check the adequacy of available clinical evidence and risk management and identify any gaps (Article 61)
	Review product labelling (Annex I Chapter III)
	Ensure post-market surveillance (PMS) arrangements are adequate (Chapter VII Section 1)
	Prepare a post-market clinical follow-up plan (PMCF, Annex XIV Part B)
	Get ready for the new vigilance requirements (Chapter VII Section 2)
	Ensure the respect of traceability obligations (Chapter III)
3 Quality Management System (QMS)	Review adequacy of QMS to meet standards and processes for medical devices under the new Regulation
	Build new regulatory requirements into the QMS
	Identify/hire the person(s) responsible for regulatory compliance within your organisation (Article 15) and be sure they are adequately qualified and trained.

Health and Food Safety

4 Legal entities	Clarify how the company is affected: legal entities, obligation of economic operators, organisational structures and resources
	Consider organisational challenges: management awareness, staffing capability and availability, budget implications
	Ensure product liability insurance is adequate
5 Portfolio	Do a cost/benefit analysis for your product portfolio; bear in mind costs for the possibl upgrade of risk class of MDs and for the new procedures for conformity assessment as well as the costs for post-market surveillance and gaps in the technical documentation, and plan your transition to the MDR accordingly
	Review supply chain provisions, and clarify roles and responsibilities of business partners (authorised representatives, importers, distributors)
6 Master implementation plan	Build a roadmap for implementation, including definition of sub-projects, resource requirements and a steering group, and ensure overall responsibility for MDR implementation has been established
	Give special consideration to certificate expiry dates, bearing in mind the transitional period, transitional provisions and availability of your Notified Bodies
7 Notified Bodies	Contact the selected Notified Bodies and determine their capacity and availability to service the implementation plan
8 Regulatory training	Empower and train staff through MDR implementation and transition workshops
9 Execute master implementation plan	Implement the various sub-projects (clinical evaluation, technical documentation, relation with other economic operators, Unique Device Identification, labelling, registration, post-market surveillance, vigilance, and reporting IT systems)
	Ensure a cross-functional project management team is in place to cover all aspects of implementation
	Ensure overall and individual responsibilities for MDR implementation have been established
10 Review efficiency and effectiveness	Implement regular meetings on project status and progress, discrepancy and gap analyses, risks, next steps and requirements
	Hold regular progress reviews against the MDR implementation plan and include these in the management review process
11 Notified Body submission	Discuss submission dates to avoid delays in the approval process
12 Ongoing monitoring	Actively monitor the still-developing European regulatory environment and guidelines expected in the coming months (check <i>European Commission</i> page on medical devices and subscribe to the newsletter)
	Establish a procedure for dealing with unannounced inspections from Notified Bodies
	Regularly review the MDR implementation plan, identifying and addressing key areas of risk



01/08/2020

© European Union, [2020] Reuse is authorised provided the source is acknowledged. The reuse policy of European Commission documents is regulated by Decision 2011/833/EU (OJ L 330, 14.12.2011, p. 39).

https://ec.europa.eu/health/ md_newregulations/overview_en

Funded under the Third EU Health Programme